One potential mechanism of synergy is that both inhibition of the mitogenic signaling pathway that regulates D-type cyclins, and blocking of CDK4/6 activities, are necessary for a synergized therapy to prevent tumor cell proliferation (81). This evidence concerns the gene CDK4 and neoplasm.